Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Axovant's Cupboard Is Bare After Lead Dementia Program Fails

Executive Summary

'New year, new me' is a mantra to be adopted by Swiss drug developer Axovant as it seeks new products to fill its pipeline. The CNS-focused company is floundering having ended development of its lead compound intepirdine following another clinical trial failure.

Advertisement

Related Content

Clinical Trials In Review: Big Hits And Misses In 2018
Axovant Closes Chapter On Failed, Second-Rate Small Molecule Strategy
Roivant Cuts Jobs, Reallocates Staff As It Prepares To Put New Stars In The Spotlight
Could Probiodrug Represent A New Era Of Alzheimer's R&D Progress?
A Status Check Of The Alzheimer’s Trial Landscape
Disappointed, Yes, But Roivant's Not Roiled By Axovant's Alzheimer's Failure

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100171

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel